First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.

Details

Language :

English

ISSN :

20959907

Volume :

9

Issue :

1

Database :

Complementary Index

Journal :

Signal Transduction & Targeted Therapy

Publication Type :

Academic Journal

Accession number :

176282474

Full Text :

https://doi.org/10.1038/s41392-024-01773-9